nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2021-25-1-18-30nefr-1928Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПодходы к лечению диабетической нефропатии (обзор литературы)Therapy approaches in diabetic nephropathy (review of literature)https://orcid.org/0000-0002-0295-3724БагрийА. Э.BagriyA. В.

Профессор Багрий Андрей Эдуардович - доктор медицинских наук, кафедра внутренних болезней № 2, заведующий кафедрой.

283003, Донецкая Народная Республика (Украина), г. Донецк, пр. Ильича, д. 16, Тел. раб. (деканат факультета интернатуры и последипломного образования): +38(062)344-40-78, моб.+38(071)317-31-98, +38(066)605-38-73 (Viber)

Chair of Internal Medicine №2, chief of the chair.

283003, Donetsk People’s Republic (Ukraine), Donetsk, Illicha Ave, 16, Phone: +38 (062)3444078 (post-graduate education faculty); mob. +38(071)317-31-98, +38(066) 605-38-73(Viber)

bagriyae@mail.ruХоменкоМ. В.KhomenkoM. V.

Доцент Хоменко Марина Владимировна - кандидат медицинских наук, факультет интернатуры и последипломного образования, кафедра терапии им. профессор А.И. Дядыка.

283003, Донецкая Народная Республика (Украина), Донецк, пр. Ильича, д. 16, Тел.: +38(071)331-46-88; +38 (050)202-86-88 (Viber)

Associated prof. Marina V. Khomenko - (MD, PhD), Post-graduate education Faculty, Chair of therapy named after professor A.I. Dyadyk, docent.

283003, Donetsk People’s Republic (Ukraine), Donetsk, Illicha Ave, 16, Phone: +38(071)331-46-88; +38 (050)202-86-88 (Viber)

mv.homenko@gmail.comШвероваО. И.ShverovaO. I.

Шверова Олеся Игоревна - кафедра внутренних болезней № 2, ординатор.

283003, Донецкая Народная Республика (Украина), Донецк, пр. Ильича, д. 16, Тел. +38(071)419-17-46

Olesya I. Shverova (MD) - Chair of Internal Medicine №2, resident.

283003, Donetsk People’s Republic (Ukraine), Donetsk, Illicha Ave, 16, Phone: Тел. +38(071)419-17-46

alesyashverova@mail.ruТитиевскаяА. И.TitievskayaE. R.

Титиевская Анастасия Ильинична - кафедра внутренних болезней № 2, ординатор

283003, Донецкая Народная Республика (Украина), Донецк, пр. Ильича, д. 16, Тел. +38(071)345-59-14

Anastasiya I. Titievskaya (MD) - Chair of Internal Medicine №2, resident

283003, Donetsk People’s Republic (Ukraine), Donetsk, Illicha Ave, 16, Phone: +38(071) 345-59-14

aa.titievskaya@gmail.comГосударственная образовательная организация Высшего профессионального образования Донецкий национальный медицинский университет им. М. ГорькогоУкраинаState Educational Organization of High Professional Education System Donetsk national medical university named after M. GorkiyUkraine2021210120212511830Copyright © Багрий А.Э., Хоменко М.В., Шверова О.И., Титиевская А.И., 20212021Багрий А.Э., Хоменко М.В., Шверова О.И., Титиевская А.И.Bagriy A.В., Khomenko M.V., Shverova O.I., Titievskaya E.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/1928

Диабетическая нефропатия (ДНП) развивается у 30-40 % больных сахарным диабетом (СД) 1 и 2 типа. Это ведущая причина терминальной стадии почечной недостаточности (тПН) в мире. Доля людей с ДНП в структуре пациентов, получающих лечение заместительной почечной терапии, достигает 40 %. ДНП ассоциируется со значительным ухудшением сердечно-сосудистого прогноза. За последние 5 лет произошли существенные изменения в подходах к лечению лиц с ДНП (включая рено- и кардиопротекцию). Они касаются, прежде всего, появления новых антигипергликемических препаратов, которые в серьезных рандомизированных контролируемых исследованиях (РКИ) показали положительное влияние на прогноз при диабете в целом и ДНП в частности. Изменения во взглядах на тактику лечения ДНР уже зафиксированы в ряде серьезных международных и отечественных нормативных документов, обсуждение основных положений которых явилось целью настоящего обзора литературы. Обзор посвящен основным терапевтическим подходам при диабетической нефропатии в соответствии с текущими отечественными и международными рекомендациями с акцентом на результаты рандомизированных контролирующих исследований по применению блокаторов ренин-ангиотензин-альдостероновой системы и различных классов антитромботических, гиполипидемических, гипогликемических средств.

Diabetic nephropathy (DNP) develops in 30-40 % of patients with type 1 and 2 diabetes mellitus (DM). It is the leading cause of the end-stage renal disease (ESRD) in the world. The proportion of people with DNP in the structure of patients receiving treatment with the replacement of renal function reaches 40 %. DNP is associated with a significant worsening of the cardiovascular prognosis. Over the past 5 years, significant changes have taken place in the approaches to the treatment of persons with DNP (including both reno- and cardioprotection). They concern, first of all, the emergence of new antihyperglycemic drugs, which have shown in serious randomized controlled trials (RCTs) beneficial effects on prognosis in diabetes in general and in DNP, in particular. Changes in views on treatment tactics for DNI have already been recorded in a number of serious international and domestic regulatory documents, the discussion of the main positions of which was the purpose of this literature review. The review is devoted to main therapeutic approaches in diabetic nephropathy according to current home and international Guidelines with focusing on randomized controlling investigations results on using renin-angiotensin-aldosterone-system blockers and antithrombotic, hypolipidemic, hypoglycemic agents different classes.

диабетическая нефропатиямедикаментозное лечениеdiabetic nephropathyconservative managementReferencesДедов ИИ, Шестакова МВ, Майоров АЮ и др. Сахарный диабет 2 типа у взрослых. Клинические Рекомендации. Сах диаб 2020;23(S2):36-41. doi: 10.14341/DM23S2Dedov II, Shestakova MV, Mayorov AYu et al. Diabetes mellitus type 2 in adults. Sah diab 2020;23(S2):4-102. (In Russ.) doi: 10.14341/DM23S2Томилина НА. Хроническая болезнь почек. Избранные главы нефрологии. ГЭОТАР-Медиа, М., 2017; 136 c.Tomilina NA. Chronic kidney disease. Selected chapters of nephrology. GEOTAR-Media, M., 2017; 136 p. (In Russ.)Gomez LA, Lei Y, Devarapu SK, Anders H-J. The diabetes pandemic suggests unmet needs for «CKD with diabetes» in addition to «diabetic nephropathy»— implications for pre-clinical research and drug testing. Nephrol Dial Transplant 2018;33:1292-1304. doi: 10.1093/ndt/gfx219Gomez LA, Lei Y, Devarapu SK, Anders H-J. The diabetes pandemic suggests unmet needs for «CKD with diabetes» in addition to «diabetic nephropathy»— implications for pre-clinical research and drug testing. Nephrol Dial Transplant 2018;33:1292-1304. doi: 10.1093/ndt/gfx219Смирнов АВ, Добронравов ВА, Кисина АА и др. Клинические рекомендации по диагностике и лечению диабетической нефропатии. Нефрология 2015; 19(1):67-77Smirnov AV, Dobronravov VA, Kisina AA et al. Clinical practice guideline for diagnostics and treatment of diabetic nephropathy. Nephrology (Saint Petersburg) 2015;19(1):67-77. (In Russ.)Pugliese G, Penno G, Natali A et al. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. J Nephrol 2020;33(1):9-35. doi: 10.1007/s40620-019-00650-xPugliese G, Penno G, Natali A et al. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. J Nephrol 2020;33(1):9-35. doi: 10.1007/s40620-019-00650-xAlicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017;12(12):2032-2045. doi: 10.2215/CJN.11491116Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017;12(12):2032-2045. doi: 10.2215/CJN.11491116American Diabetes Association. Microvascular complications and foot care: Standards of Medical Care in Diabetes. Diabetes Care 2020;43(S1):S135-S151. doi: 10.2337/dc20-S004American Diabetes Association. Microvascular complications and foot care: Standards of Medical Care in Diabetes. Diabetes Care 2020;43(S1):S135-S151. doi: 10.2337/dc20-S004Cosentino FGPJ, Aboyans V, Bailey C.J. et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2020;41(2):255-323. doi: 10.1093/eurheartj/eht108Cosentino FGPJ, Aboyans V, Bailey C.J. et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2020;41(2):255-323. doi: 10.1093/eurheartj/eht108de Boer IH, Caramori ML, Chan JCN et al. Executive summary of the 2020 KDIGO Diabetes management in CKD Guideline: Evidence-based advances in monitoring and treatment. Kidney Int 2020; (In Press) https://doi.org/10.1016/j.kint.2020.06.024de Boer IH, Caramori ML, Chan JCN et al. Executive summary of the 2020 KDIGO Diabetes management in CKD Guideline: Evidence-based advances in monitoring and treatment. Kidney Int 2020; (In Press) https://doi.org/10.1016/j.kint.2020.06.024Шестакова МВ, Шамхалова МШ, Ярек-Мартынова ИЯ и др. Федеральные клинические рекомендации по диагностике, скринингу, профилактике и лечению хронической болезни почек у больных сахарным диабетом. М., 2014; 1-39Shestakova MV, Shamkhalova MSh, Yarek-Martynova IYa et al. Federal clinical guidelines for the diagnosis, screening, prevention and treatment of chronic kidney disease in patients with diabetes mellitus. М., 2014; 1-39. (In Russ.)Ruiz-Ortega M, Rodrigues-Diez RR, Lavoz C, Rayego-Mateos S. Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”. J Clin Med 2020;9(3):813. doi: 10.3390/jcm9030813Ruiz-Ortega M, Rodrigues-Diez RR, Lavoz C, Rayego-Mateos S. Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”. J Clin Med 2020;9(3):813. doi: 10.3390/jcm9030813Добронравов ВА, Шестакова МВ. Нефрология. Национальное руководство. ГЭОТАР-Медиа, М., 2016; 337-349Dobronravov VA, Shestakova MV. Nephrology. National guide. GEOTAR-Media, M., 2016; 337-349. (In Russ.)Arnett DK, Blumenthal RS, Albert MA et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e596-e646. doi: 10.1161/CIR.0000000000000678Arnett DK, Blumenthal RS, Albert MA et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e596-e646. doi: 10.1161/CIR.0000000000000678Evert AB, Dennison M, Gardner CD et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care 2019;42: 731-754. doi: 10.2337/dci19-0014Evert AB, Dennison M, Gardner CD et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care 2019;42: 731-754. doi: 10.2337/dci19-0014Manfredini F, Mallamaci F, D'Arrigo G et al. Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial. J Am Soc Nephrol 2017; 28: 1259-1268. doi: 10.1681/ASN.2016030378Manfredini F, Mallamaci F, D'Arrigo G et al. Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial. J Am Soc Nephrol 2017; 28: 1259-1268. doi: 10.1681/ASN.2016030378Zelle DM, Klaassen G, van Adrichem E et al. Physical inactivity: a risk factor and target for intervention in renal care. Nat Rev Nephrol 2017;13:152-168. doi: 10.1038/nrneph.2016.187Zelle DM, Klaassen G, van Adrichem E et al. Physical inactivity: a risk factor and target for intervention in renal care. Nat Rev Nephrol 2017;13:152-168. doi: 10.1038/nrneph.2016.187Kopel J, Pena-Hernandez C, Nugent K. Evolving spectrum of diabetic nephropathy. World J Diabetes 2019;10(5):269-279. doi: 10.4239/wjd.v10.i5.269Kopel J, Pena-Hernandez C, Nugent K. Evolving spectrum of diabetic nephropathy. World J Diabetes 2019;10(5):269-279. doi: 10.4239/wjd.v10.i5.269Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int 2017;92(3):313-323. doi:10.1016/j.kint.2016.12.034Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int 2017;92(3):313-323. doi:10.1016/j.kint.2016.12.034Formanek P, Salisbury-Afshar E, Afshar M. Helping Patients With ESRD and Earlier Stages of CKD to Quit Smoking. Am J Kidney Dis 2018;72(2):255-266. doi: 10.1053/j.ajkd.2018.01.057Formanek P, Salisbury-Afshar E, Afshar M. Helping Patients With ESRD and Earlier Stages of CKD to Quit Smoking. Am J Kidney Dis 2018;72(2):255-266. doi: 10.1053/j.ajkd.2018.01.057Unger T, Borghi C, Charchar F et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020;75:1334-1357. doi: 10.1161/hypertensio-naha.120.15026Unger T, Borghi C, Charchar F et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020;75:1334-1357. doi: 10.1161/hypertensio-naha.120.15026Williams B, Mancia G, Spiering W et al. 2018 ESC / ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy33Williams B, Mancia G, Spiering W et al. 2018 ESC / ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy33Багрий АЭ, Дядык АИ, Хоменко МВ и др. Гиполипи-демические препараты: возможности и перспективы применения. Сообщение 3. Применение статинов у отдельных категорий больных. Атеросклероз 2016;12(3):61-77Bagriy AE, Dyadyk AI, Khomenko MV et al. Hypolipidemic medications: current use and future perspectives. Part 3. Statin’s using in different patient’s category. Ateroscleroz 2016;12(3):61-77. (In Russ.)Grundy SM, Stone NJ, Bailey AL et al. AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol 2019;73(24):e285-e350. doi: 10.1016/j.jacc.2018.11.003Grundy SM, Stone NJ, Bailey AL et al. AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol 2019;73(24):e285-e350. doi: 10.1016/j.jacc.2018.11.003Pryor JB, Weber BR, Weber JV et al. Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. Drugs Ther Perspect 2019;35:431-441. https://link.springer.com/ar-ticle/10.1007/s40267-019-00646-4Pryor JB, Weber BR, Weber JV et al. Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. Drugs Ther Perspect 2019;35:431-441. https://link.springer.com/ar-ticle/10.1007/s40267-019-00646-4Kosmas CE, DeJesus E, Souria E et al. Effects of statins on cardiovascular outcomes in patients with chronic kidney disease. Clin Med Insights:Therapeutics 2017;9:1-5. doi: 10.1177/1179559X17719029Kosmas CE, DeJesus E, Souria E et al. Effects of statins on cardiovascular outcomes in patients with chronic kidney disease. Clin Med Insights:Therapeutics 2017;9:1-5. doi: 10.1177/1179559X17719029Eknoyan G, Lameire N, Eckardt K-U et al. KDIGO 2012 Clinical practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):1-150. doi:10.1038/kisup.2012.73Eknoyan G, Lameire N, Eckardt K-U et al. KDIGO 2012 Clinical practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):1-150. doi:10.1038/kisup.2012.73Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? Quart J Med 2017;110(8):493-500. doi: 10.1093/qjmed/hcx040Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? Quart J Med 2017;110(8):493-500. doi: 10.1093/qjmed/hcx040Newman CB, Preiss D, Tobert JA et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis and Vascular Biology 2019;39(2):e38-e81. doi:10.1161/ATV.0000000000000073Newman CB, Preiss D, Tobert JA et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis and Vascular Biology 2019;39(2):e38-e81. doi:10.1161/ATV.0000000000000073Багрий АЭ, Дядык АИ, Хоменко МВ и др. Гиполипиде-мическе препараты: возможности и перспективы применения. Сообщение 1. Нестатиновые гиполипидемические лекарственные средства. Атеросклероз 2016;12(1):61-68Bagriy AE, Dyadyk AI, Khomenko mV et al. Hypolipidemic medications: current use and future perspectives. Part 1. Non-statin hypolipidemic medications. Ateroscleroz 2016;12(1):61-68. (In Russ.)Knuuti J, Wijns W, Saraste A et al. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J 2020;41:407-477. doi: 10.1093/eurheartj/ehz425Knuuti J, Wijns W, Saraste A et al. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J 2020;41:407-477. doi: 10.1093/eurheartj/ehz425Смолина МО, Бенимецкая КС, Рагино ЮИ, Воевода МИ. PCSK9: новые победы и горизонты. Атеросклероз 2018;14(3):70-77. doi: 10.15372/ATER20180311Smolina MO, Benimetskaya KS, Ragino YI, Voevoda MI. PCSK9: new victory and horizons. Ateroscleroz. 2018;14(3):70-77. (In Russ.) doi: 10.15372/ATER20180311Shivakumar O, Sattar N, Wheeler DC. Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease. Nephrol Dial Transplant 2020;35:i43-i47. doi: 10.1093/ndt/gfz292Shivakumar O, Sattar N, Wheeler DC. Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease. Nephrol Dial Transplant 2020;35:i43-i47. doi: 10.1093/ndt/gfz292Шумилова НА, Павлова СИ. Глифлозины: гликемические и негликемические эффекты. Acta medica Eurasica 2019;1:44-51 URL: http://acta-medica-eurasica.ru/single/2019/1/6/Shumilova NA, Pavlova SI. Glyphlosine derivatives: glycemic and non-glycemic effects. Acta medica Eurasica 2019;1:44-51. (In Russ.). URL: http://acta-medica-eurasica.ru/single/2019/1/6/Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-39. doi: 10.1016/S0140-6736(18)32590-XZelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-39. doi: 10.1016/S0140-6736(18)32590-XCherney DZ, Kanbay M, Lovshin JA. Renal physiology of glucose handling and therapeutic implications. Nephrol Dial Transplant 2020;35:i3-i12. doi: 10.1093/ndt/gfz230Cherney DZ, Kanbay M, Lovshin JA. Renal physiology of glucose handling and therapeutic implications. Nephrol Dial Transplant 2020;35:i3-i12. doi: 10.1093/ndt/gfz230Heerspink HJL, Stefansson BV, Chertow GM et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant 2020;35:274-282. doi: 10.1093/ndt/gfz290Heerspink HJL, Stefansson BV, Chertow GM et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant 2020;35:274-282. doi: 10.1093/ndt/gfz290Bonora BM, Avogaro A., Fadini GP. Extraglycemic effects of SGLT2 Inhibitors: A review of the evidence. Diabetes Metab Syndr Obes 2020;13:161-174. doi: 10.2147/DMSO.S233538Bonora BM, Avogaro A., Fadini GP. Extraglycemic effects of SGLT2 Inhibitors: A review of the evidence. Diabetes Metab Syndr Obes 2020;13:161-174. doi: 10.2147/DMSO.S233538Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018;11(6):749-761. doi:10.1093/ckj/sfy090Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018;11(6):749-761. doi:10.1093/ckj/sfy090Багрий АЭ, Супрун ЕВ, Михайличенко ЕС, Голодников ИА. Хроническая сердечная недостаточность и сахарный диабет 2 типа: состояние проблемы. Российский кардиологический журнал 2020;25(4):79-85. doi:10.15829/1560-4071-2020-3858Bagriy AE, Suprun YeV, Mykhailichenko IS, Golodnikov IA. Chronic heart failure and type 2 diabetes: state of the problem. Russ J Cardiol 2020;25(4):79-85. (In Russ.)Tager T, Atar D, Agewall S et al. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Fail Rev Apr 2020; (In Press). doi: 10.1007/s10741-020-09954-8Tager T, Atar D, Agewall S et al. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Fail Rev Apr 2020; (In Press). doi: 10.1007/s10741-020-09954-8Gorriz JL, Navarro-Gonzalez JF, Ortiz A et al. Sodiumglucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrol Dial Transplant 2020;35:i13-i23. https://doi: 10.1093/ndt/gfz237Gorriz JL, Navarro-Gonzalez JF, Ortiz A et al. Sodiumglucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrol Dial Transplant 2020;35:i13-i23. https://doi: 10.1093/ndt/gfz237Lo KB, Gul F, Ram P et al. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. Cardiorenal Med 2020;10:1-10. doi: 10.1159/000503919Lo KB, Gul F, Ram P et al. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. Cardiorenal Med 2020;10:1-10. doi: 10.1159/000503919Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-657. doi: 10.1056/NEJMoa1611925Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-657. doi: 10.1056/NEJMoa1611925Neuen BL, Young T, Heerspink HJL et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019;7:845-854. doi: 10.1016/S2213-8587(19)30256-6Neuen BL, Young T, Heerspink HJL et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019;7:845-854. doi: 10.1016/S2213-8587(19)30256-6Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-2306. doi: 10.1056/NEJMoa1811744Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-2306. doi: 10.1056/NEJMoa1811744Kristensen SL, Rorth R, Jhund PS et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-anal-ysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776-785. doi: 10.1016/s2213-8587(19)30249-9Kristensen SL, Rorth R, Jhund PS et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-anal-ysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776-785. doi: 10.1016/s2213-8587(19)30249-9Tuttle KR, Lakshmanan MC, Rayner B et al. Dulaglu-tide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018;6:605-617. doi: 10.1016/S2213-8587(18)30104-9Tuttle KR, Lakshmanan MC, Rayner B et al. Dulaglu-tide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018;6:605-617. doi: 10.1016/S2213-8587(18)30104-9

The authors declare that there are no conflicts of interest present.